DR info

臨床試験数 : 6 / 薬物数 : 6 - (DrugBank : 4) / 標的遺伝子数 : 9 - 標的パスウェイ数 : 14

薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。

Copper
   Hamamatsu University School of Medicine
      2014   -   JPRN-UMIN000030626   Japan;
   Kobe Unniversitu Graduate School of Medicine
      2011   -   JPRN-UMIN000005259   Japan;
Copper Histidinate
   Cyprium Therapeutics, Inc.
      2019   -   NCT04074512   -
Copper Histidine
   Cyprium Therapeutics, Inc.
      2009   Phase 3   NCT00811785   United States;
   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
      1990   Phase 1/Phase 2   NCT00001262   United States;
Diethyldithiocarbamate
   Kobe Unniversitu Graduate School of Medicine
      2011   -   JPRN-UMIN000005259   Japan;
Droxidopa
   Stephen G. Kaler, MD
      2021   Phase 1/Phase 2   NCT04977388   United States;
Histidine
   Hamamatsu University School of Medicine
      2014   -   JPRN-UMIN000030626   Japan;
   Kobe Unniversitu Graduate School of Medicine
      2011   -   JPRN-UMIN000005259   Japan;
Long Term Follow-Up
   Cyprium Therapeutics, Inc.
      2019   -   NCT04337684   United States;